title: Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
abstract: Obesity-related hormones and cytokines alter PI3 K-AKT-mTOR pathway activation in breast tumors contributing to poorer disease-free survival (DFS) and decreased responsiveness to tamoxifen and trastuzumab. We hypothesized that single nucleotide polymorphisms (SNPs) in candidate genes in the PI3 K-AKT-mTOR signaling pathway may act as genetic modifiers of breast cancer DFS. We analyzed the association of 106 tagging SNPs in 13 genes (ADIPOQ, IGF1, INS, IRS1, LEP, LEPR, LEPROT, PIK3CA, PIK3R5, PTEN, TSC1, TSC2, and AKT1) in the P13K-AKT-mTOR pathway with DFS in a sample of 1,019 women with stage I-II breast cancer. SNPs significantly associated with DFS in any genetic model (additive, dominant, or recessive) after correcting for false discovery rate (FDR = 0.10) were included in Cox proportional hazards multivariable analyses. After adjusting for race/ethnicity, age at diagnosis, tumor stage, and treatment, rs1063539 in ADIPOQ, rs11585329 in LEPR, and rs2519757 in TSC1 were associated with improved DFS, and rs1520220 in IGF1 and rs2677760 in PIK3CA were associated with worse DFS. The associations were not significantly modified by the type of systemic treatment received or body mass index. The SNPs were not associated with tumor characteristics such as tumor size, lymph node status, nuclear grade, or hormone receptor status. In this study, germline SNPs in the PI3 K-AKT-mTOR pathway were associated with breast cancer DFS and may be potential prognostic markers. Future studies are needed to replicate our results and to evaluate the relationship between these polymorphisms and activation of the PI3 K-AKT-mTOR pathway in breast tumors.
authors.affiliation: Department of Gastroenterology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
authors.forename: Mala
authors.initials: M
authors.lastname: Pande
authors.forename: Melissa L
authors.initials: ML
authors.lastname: Bondy
authors.forename: Kim-Anh
authors.initials: KA
authors.lastname: Do
authors.forename: Aysegul A
authors.initials: AA
authors.lastname: Sahin
authors.forename: Jun
authors.initials: J
authors.lastname: Ying
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Thompson
authors.forename: Abenaa M
authors.initials: AM
authors.lastname: Brewster
mesh_terms: D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009765:Obesity / Q000201:enzymology / Q000235:genetics*; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics*; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000235:genetics*
chemical_list: D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human
references.citation: Breast Cancer Res. 2013;15(5):R96
references.pmid: 24131622
references.citation: Breast Cancer Res Treat. 2011 Jul;128(2):447-56
references.pmid: 21594665
references.citation: Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73
references.pmid: 24390424
references.citation: Cancer Cell. 2007 Oct;12(4):395-402
references.pmid: 17936563
references.citation: Genes Dev. 2004 Aug 15;18(16):1926-45
references.pmid: 15314020
references.citation: Cytokine Growth Factor Rev. 2013 Dec;24(6):503-13
references.pmid: 24210902
references.citation: J Pathol. 2005 Oct;207(2):139-46
references.pmid: 16088978
references.citation: Oncol Rep. 2008 May;19(5):1099-107
references.pmid: 18425364
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6382S-7S
references.pmid: 15448035
references.citation: Oncogene. 2006 Oct 16;25(48):6416-22
references.pmid: 17041626
references.citation: Clin Cancer Res. 2012 Dec 15;18(24):6784-91
references.pmid: 23092874
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1719-22
references.pmid: 18628423
references.citation: Cancer Cell. 2004 Aug;6(2):117-27
references.pmid: 15324695
references.citation: Clin Cancer Res. 2007 Oct 1;13(19):5883-8
references.pmid: 17908983
references.citation: Carcinogenesis. 2010 Aug;31(8):1387-91
references.pmid: 20530239
references.citation: Histopathology. 2011 Jun;58(7):1054-63
references.pmid: 21707707
references.citation: Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
references.pmid: 16341064
references.citation: Am J Hum Genet. 2004 Jan;74(1):106-20
references.pmid: 14681826
references.citation: Neoplasia. 2011 Jun;13(6):504-15
references.pmid: 21677874
references.citation: Cancer. 2013 Mar 15;119(6):1140-8
references.pmid: 23065954
references.citation: Breast Cancer Res. 2011 May 19;13(3):R52
references.pmid: 21595894
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2877-87
references.pmid: 20810604
references.citation: Nat Rev Cancer. 2004 May;4(5):335-48
references.pmid: 15122205
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):880-8
references.pmid: 18398029
references.citation: J Mol Endocrinol. 2011 Jun 17;47(1):R1-10
references.pmid: 21498522
references.citation: Genome Res. 2005 Nov;15(11):1592-3
references.pmid: 16251469
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4438-44
references.pmid: 17785707
references.citation: Lancet Oncol. 2010 Jun;11(6):530-42
references.pmid: 20472501
references.citation: Cancer. 2012 Jul 1;118(13):3356-64
references.pmid: 22038736
references.citation: Breast. 2013 Dec;22(6):1155-60
references.pmid: 23968866
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2553-7
references.pmid: 19723917